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Abstract Skull metastases are malignant bone tumors
which are increasing in incidence. The objectives of this
study were to characterize the MR imaging features, loca-
tions, and extent of metastatic skull tumors to determine the
frequency of the symptomatic disease, and to assess patient
outcomes. Between September 2002 and March 2008, 175
patients undergoingroutineheadMRimagingwerefoundto
have metastatic skull tumors. Contrast-enhanced study with
fat suppression was used in some cases when required.
Classiﬁcation of metastases was simpliﬁed to three yes/no
questions: ﬁrst, with regard to location (either in the cal-
varium or in the cranial base); second, with regard to dis-
tribution within the plane of the cranial bone (either
‘‘circumscribed’’ meaning clearly demarcated and conﬁned
toone bone, or ‘‘diffuse’’ andlikelytospreadacrossa suture
to another bone); and third, with regard to invasion
(‘‘intraosseous’’ in cranial bones only, or ‘‘invasive’’
spreading from the skull, either out into the scalp or inward
to the dura and perhaps further in). Primary sites were breast
cancer (55%), lung cancer (14%), prostate cancer (6%),
malignant lymphoma (5%), and others (20%). The mean
time from primary diagnosis to skull metastasis diagnosis
was 71 months for cases of breast cancer, 26 months for
prostate cancer, 9 months for lung cancer, and 4 months for
malignant lymphoma. Calvarial circumscribed intraosseous
metastases were found most frequently (27%). The patients
were mainly asymptomatic. However, some patients suf-
fered from local pain or cranial nerve palsies that harmed
their quality of life. Treatment, mainly for symptomatic
cases, was by local or whole-skull irradiation. Metastatic
skull tumors are not rare, and most are calvarial circum-
scribed intraosseous tumors. MR images contribute to
understanding their type, location, and multiplicity, and
their relationship to the brain, cranial nerves, and dural
sinuses. Radiation therapy improved the QOL of patients
with neurological symptoms.
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Introduction
The cranium is the site of blood-born metastases of vari-
ous malignancies including carcinoma of the lung, breast,
and thyroid, renal cell carcinoma, malignant melanoma in
adults, and neuroblastoma in children. Although skull
metastases are not rare, and can cause disabling clinical
syndromes including pain, they remain neglected compli-
cations of systemic malignancies [1]. They are manageable,
but early diagnosis is crucial for selecting treatment.
Although CT scan is commonly considered appropriate for
bone lesion diagnosis, MR images enable screening for
metastases in both skull bone and brain. The objective of
this study was to present clinical features and outcomes of
patients with skull metastases examined in a district cancer
center. On the basis of the available data, we suggest
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bution within and perpendicular to the plane of the bone, as
described by three questions answerable by MRI screening.
Subjects and methods
From September 2002 to March 2008, 175 patients with
calvarial and skull-base metastases were identiﬁed from the
institute date-base. Clinical information was obtained by
retrospective chart review, on age, sex, type of primary
tumor, presenting symptoms, treatment, systemic metasta-
ses, and survival.
Magnetic resonance (MR) images were reviewed to
analyze the location, to see whether a tumor invaded any
cranial suture, scalp, dura, or brain, and to assess signal
intensity and contrast-enhancement features. Any associ-
ated intracranial metastases or meningeal dissemination
were also recorded.
Imaging procedures
MRI studies were performed with the units Signa 1.5
T (GE Healthcare) and Intera 1.5 T (Philips Healthcare).
The imaging procedures used, which depended on the
condition of the patients, were: T1-weighted images (TR/
TE, 480-530/15, Signa; 408-449/12, Intera), T2-weighted
images (3500–3750/102, Signa; 3751–4126/90, Intera),
FLAIR images (9000/125, 2,250-ms inversion time, Signa;
6000/100, 2,000-ms inversion time, Intera), and contrast-
enhanced T1-weighted images with 0.1 mmol/kg gado-
pentetate dimeglumine (Magnevist, Bayer Healthcare). Fat
suppression was added to gadolinium-contrast T1-weighted
images (430–530/15, Signa; 425–475/12, Intera) when the
attending physician requested investigation of bone mar-
row changes.
Imaging ﬁnding and classiﬁcation
A neuroradiologist and two neurosurgeons evaluated the
images. Classiﬁcation of metastases was simpliﬁed to three
yes/no questions: ﬁrst, with regard to location (either in the
calvarium or in the cranial base); second, with regard to
distribution within the plane of the cranial bone (either
‘‘circumscribed’’, meaning conﬁned to one bone, or
‘‘diffuse’’ and likely to spread across a suture to another
bone); and third, with regard to invasion (‘‘intraosseous’’
or ‘‘invasive’’ spreading out of the bone, either out into the
scalp or inward to the dura). Thus each lesion could be
described by its location and by its distribution within and
perpendicular to the plane of the bone.
Because histologic conﬁrmation of skull metastases was
not generally available, diagnosis was based primarily on
results from subsequent MR images and other standard
diagnostic modalities: CT and radionuclide bone scanning.
No cases of skull-base invasion were included in which
a regional primary tumor of the head and neck directly
inﬁltrated along the cranial nerves.
The study protocol was approved by the Institutional
Review Board and conducted according to the principles of
the Declaration of Helsinki and the rules of Good Clinical
Practice.
Results
Patient characteristics
Table 1 lists the clinical features of 175 patients. The
patients’ median age was 57 years (range 8–82 years). The
ratio of men to women was 3:7. Breast cancer (in 54.9%)
was the most common primary tumor, followed by lung
cancer (in 14.3%), prostate cancer (in 6.3%), malignant
lymphoma (in 5.1%), and others (in 19.4%).
Among the primary lung cancer cases, the most com-
mon histological types were adenocarcinoma (58%),
Table 1 Patients’ characteristics
Characteristics N = 175
Sex
Women 122 (70%)
Men 53 (30%)
Median age at diagnosis of skull metastases (range) 57 (8–82)
Primary cancer
Breast 96 (54.9%)
Lung 25 (14.3%)
Prostate 11 (6.3%)
Malignant lymphoma 9 (5.1%)
Gastric 7 (4.0%)
Esophagus 5 (2.9%)
Malignant melanoma 4 (2.3%)
Leukemia 4 (2.3%)
Colon 2 (1.1%)
Liver 2 (1.1%)
Orbit 1 (0.6%)
Thyroid 1 (0.6%)
Thymoma 1 (0.6%)
Intestine 1 (0.6%)
Cartinoid 1 (0.6%)
Uterus cervical 1 (0.6%)
Uterus body 1 (0.6%)
Urinary duct 1 (0.6%)
Bladder 1 (0.6%)
Unknown 1 (0.6%)
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123followed by small cell carcinoma (18%), squamous cell
carcinoma (8%), large cell carcinoma (8%), and unknown
(8%).
Fifty-two (30%) of all 175 patients had brain parenchy-
mal metastases at their presentation. As for the primary
sites, 33% of patients with lung cancer had both brain and
skull metastases, as did 19% of patients with breast cancer;
however, no patient with prostatic cancer had brain paren-
chymal lesions.
MR features
Metastases were found in calvarial bones in 121 patients,
and in the skull base in 97 patients, so there were 43
patients with both (Table 2).
MR signals varied; there were low to iso-intensity sig-
nals on T1-weighted, and low to iso-intensity signals on
T2-weighted images. Skull metastases were enhanced by
gadolinium to different degrees; most lesions showed
nearly homogenous enhancement, but one of the lesions
showed only rim enhancement. Examples of calvarial
metastases are presented on Fig. 1, and skull-base metas-
tases in Fig. 2.
The distribution of metastases according to the clas-
siﬁcation described above is shown in Table 2. The most
common type was calvarial circumscribed intraosse-
ous metastases (27%), followed by skull base diffuse
invasive (22%) then calvarial diffuse invasive metastases
(20%).
Metastases from breast cancer most frequently presented
as calvarial circumscribed intraosseous tumors (30 of 96
patients), followed by calvarial diffuse invasive metastases
(25 of 96 patients). Metastases from lung cancer (like those
from breast cancer) most frequently presented as calvar-
ial circumscribed intraosseous lesions (7 of 24 patients),
followed by calvarial circumscribed invasive metastases
(6 of 24 patients).
Calvarial circumscribed intraosseous lesions were the
commonest skull-bone metastases in cases of both breast-
cancer (30 of 96 breast-cancer patients) and lung-cancer
(7 of 24 lung-cancer patients).
Calvarial diffuse invasive lesions were the second-
commonest skull-bone metastases in cases of lung-cancer
(6 of 24 lung-cancer patients).
Calvarial circumscribed invasive lesions were the sec-
ond-commonest skull-bone metastases in cases of breast-
cancer (25 of 96 lung-cancer patients).
Clinical manifestations (Table 2)
Patients with calvarial circumscribed intraosseous metas-
tases had no symptoms. Calvarial circumscribed invasive
metastases caused local pain and swelling in ﬁve patients
(18%). Four patients (11%) with calvarial diffuse invasive
Table 2 MR classiﬁcation and
symptoms
a N: numbers of cases; 43
patients presented with both
b Incidence (%) in 175 patients
c Frequency (%) in each type
MR classiﬁcation Incidence (%)
b Symptom Symptomatic
cases (%)
c
Calvaria (N = 121
a)
Circumscribed
Intraosseous 27% (48/175) None 0% (0/48)
Invasive 22% (38/175) Pain 13% (5/38)
Cosmetic problem 8% (3/38)
Diffuse
Intraosseous 6% (10/175) None 0% (0/10)
Invasive 20% (30/175) Meningeal irritation 10% (3/30)
Disorientation 10% (3/30)
Skull base (N = 97
a)
Circumscribed
Intraosseous 10% (18/175) Pain 11% (2/18)
Invasive 15% (26/175) CN sign 29% (7/26)
Pain 15% (4/26)
Direct compression on the orbit 12% (3/26)
Diffuse
Intraosseous 8% (14/175) Pain 21% (3/14)
Invasive 22% (39/175) CN sign 33% (13/39)
Pain 10% (4/39)
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123metastases suffered from headache and nausea because of
dural and subdural invasion. As demonstrated in Table 2,
the most common symptom in our patients with skull-base
metastasis was cranial nerve signs (21%), followed by pain
(13%). Of 20 patients with cranial nerve signs, 11 (55%)
presented with diplopia, 4 (20%) with trigeminal nerve
Fig. 1 MR images show four
types of calvarial metastasis.
a T1-weighted image shows a
lesion of low-intensity signal
with clear margin;
circumscribed intraosseous
type. b T1-weighted image
shows an oval lesion of iso-
intensity signal invading to the
dura; circumscribed invasive
type. c T1-weighted image
shows heterogeneous bone
marrow; diffuse intraosseous
type. d T1-weight image with
contrast media shows
heterogeneous enhancement of
the parietal bone, dura and the
cortical sulci; diffuse invasive
type
Fig. 2 MR images show four
types of skull-base metastasis.
a T1-weighted image shows a
lesion of low-intensity signal
with clear margin in the right
pyramid apex; circumscribed
intraosseous type. b T1-weighted
image with contrast media shows
a multilobulated lesion in the
sphenoid bone invading the
temporal muscle and the dura;
circumscribed invasive type.
c T1-weighted image with
contrast media and fat
suppression shows diffuse
enhancement of the clivus and
pyramis apex; diffuse
intraosseous type. d T1-weighted
imagewithcontrastmediaandfat
suppression shows
heterogeneous enhancement of
the skull base and the dura of the
middle fossa; diffuse invasive
type
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123sign, 4 (20%) with hypogrossal nerve dysfunction, and 3
(15%) with facial nerve palsy.
The median interval between diagnosis of the primary
tumors and detection of skull metastases was 4 years (mean
6 years;range0–16 years5 months).Themeansurvivaltime
from skull metastasis in the 175 patients was 19.5 months
(median 9 months; range 3–65 months). The time from pri-
mary diagnosis to skull metastases was 71 months for cases
with breast cancer, 26 months for prostate cancer, 9 months
for lung cancer, and 4 months for malignant lymphoma [2]
(Table 3).
Treatment
Patients with asymptomatic skull metastases and without
brainmetastaseswerefollowedupwithregularMRimaging.
Sixty-three (36%) of our patients underwent radiation
therapy. Thirty-ﬁve (56%) of those 63 patients had simul-
taneous brain parenchymal metastases, and needed whole-
brain radiation. Another 28 patients were symptomatic
because of skull metastases: 23 (82%) patients showed
improvement of their symptoms or stable disease after local
or whole cranial radiation.
Overall survival from diagnosis of metastatic skull tumor
was 23 months for patients with prostate cancer, 15 months
for breast cancer, 6 months for malignant lymphoma, and
5 months for lung cancer (Fig. 3).
Discussion
Incidence and general consideration
Our study showed breast cancer is the most frequent source
of skull metastases both for calvarial metastases (of 122
patients) and for skull-base metastases (of 97 patients). This
contributed to the large preponderance of female vs male
patients (7:3) in our study. We found no signiﬁcant differ-
ence in primary cancer between calvarial and skull-base
metastases. There has been no study of large series
of calvarial metastases. However, a meta-analysis of 279
cases with skull-base metastases demonstrated the most
frequent primary tumor was prostate cancer (38.5%) fol-
lowed by breast (20.5%) and lymphoma (8%) [3]. Prostate
cancer may cause symptomatic skull-base metastases more
frequently than do other malignancies. Also one might
overlook skull metastases from prostate cancer, because the
patients seldom undergo brain MR imaging for screening.
Sensitivity of imaging
Cancer cells may metastasize to bone marrow, where MR
imaging is very sensitive. The normal pattern of fat dis-
tribution in the diploic space and marrow of the skull base
was symmetric. Gross asymmetry of the diploic space
alone is highly suggestive of calvarial disease on pre-
contrast and post-contrast images. MRI using T2 and
T1-weighted sequences before and after intravenous gad-
olinium administration is the best way to detect skull
metastases. Fat suppression in combination with gadolin-
ium infusion is particularly important. The main ﬁnding in
skull metastases consists of substitution of the usual
Table 3 Primary cancer and
intervals from diagnosis of
primary malignancy to skull
metastases
Primary tumor This study Greenberg et al. 1981 [2] (skull base only)
No. Median time (M, range) No. Median time (M, range)
Breast 96 (55%) 71 (1–197) 17 (40%) 66 (2–192)
Lung 25 (14%) 9 (0–40) 6 (14%) 3 (0–36)
Prostate 11 (6%) 26 (0–132) 5 (12%) 23 (1–39)
Head and neck 1 (1%) 0 (0) 6 (14%) 12 (7–72)
Lymphoma 9 (5%) 4 (0–8) 3 (7%) 20 (18–32)
Miscellaneous 34 (19%) 7 (1–61) 6 (14%) 18 (1–132)
Total 175 17 (0–197) 43 23 (0–192)
Fig. 3 Kaplan–Meier survival curve of metastatic skull tumors
(overall survival from diagnosis of metastatic skull tumors both with
and without therapy)
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123hyperintense fat sign by a hypointense lesion on non-
enhanced T1-weighted images with a variable appearance
on T2-weighted images. T1-weighted sequences with fat
suppression show variable enhancement after gadolinium
infusion [3]. MR is particularly useful to show any invasion
into the dura or cranial nerves. Careful comparison of
T2-weighted, T1-weighted, and enhanced images is crucial
for detection of subtle intradiploic metastases.
A normal adult skull base shows low and high-intensity
signals mixed in T1-weighted images and iso-intensity
with the pons in T2-weighted images. Typical MR ﬁndings
of skull-base lymphoma are iso-intense with the grey
matter on T1-weighted images, but giving high-intensity
signal on T2-weighted images, and homogenous gadolin-
ium enhancement [4, 5].
CT-scan with bone windows is a useful method to show
lytic bone lesions. However, CT scan does not clearly show
boundaries and degrees of dural invasion by bone metas-
tasis. It has poorer spatial resolution for concomitant brain
metastasis than does MR imaging.
Radionuclide bone scan offers relatively poor sensitivity
in detecting purely osteolytic bone metastases [6], because
this technique requires enhanced remodeling of bone to
become positive. Also, bone scintigraphy may be negative
when MR image is positive [7].
FDG-PET has become an important oncological tech-
nique. Diagnostic accuracy of bone metastasis was com-
parable with that of PET and bone scintigram in a recent
study [6]. However, calvarium is usually intentionally
excluded from FOV of FDG-PET scan setting because of
the large amount of glucose in the normal cranium.
Classiﬁcation of the skull metastases
The three-question classiﬁcation which we propose here
can facilitate early identiﬁcation and diagnosis of metas-
tases on checking head MR images that are taken during
routine screening or assessment of brain metastasis. Inva-
sive type metastases in particular must be carefully fol-
lowed up, even if they are asymptomatic.
Clinical presentation and symptoms
Metastatic skull tumors are clinically important for patients’
quality of life, although they may not directly inﬂuence
survival time. Calvarial metastases may cause superﬁcial
focal pain and cosmetic problems [8], and once calvarial
metastases invade into the dura and intradural space,
patients suffer from increased intracranial pressure, men-
ingeal irritation, and focal neurological signs.
Skull-base metastases usually cause various combina-
tions of cranial nerve signs. Lower cranial nerve involve-
ments are serious clinical manifestations, sometimes
causing aspiration pneumonia. Five syndromes enable
convenient understanding of the anatomical features of
skull-base tumors (Table 4). The ﬁve syndromes listed in
Table 4 illustrate the clinical features of skull-base tumors
[2]. Among those ﬁve syndromes, occipital condyle syn-
drome is of particular importance in differential diagnosis
for patients with unilateral severe occipital headache.
Cancers can metastasize to the condyle, causing severe
pain and deviation of the protruded tongue toward the side
of the pain; metastases from prostatic, colon, and other
cancers have recently been reported [9, 10]. Initial imaging
may be within normal limits in occipital condyle syn-
drome, however, patients should be followed up closely
[9]. In our series, orbital and parasellar syndromes were
frequently seen, although other syndromes were rare.
Treatment of skull metastases
Four modalities were used for patients with skull metas-
tasis: irradiation, chemotherapy, endocrinological therapy,
and surgical removal.
Conventional fractionated radiation therapy remains the
primary treatment. Vikram and Chu reported that radiation
had better effects for patients presenting with symptoms of
short duration; response rate was 87% for patients with less
than 1 month history, 69% for patients with 1–3 months
history, however, 25% for those with [3 months history
[11].
Radiosurgery provides good tumor control, with side
effects comparable with those of standard radiation therapy
[2]. Patients with larger lesions near sensitive structures or
in a previously irradiated ﬁeld might beneﬁt from the
fractionated stereotactic radiation technique.
Small-cell lung carcinomas, breast cancers, and prostate
cancers are sensitive to radiation therapy and chemother-
apy or hormone therapy. Renal cell carcinoma or mela-
noma is relatively radio-resistant.
Only a minority of patients with skull metastases are
candidates for surgical resection. Michael et al. reported
that 13 patients with metastases overlying dural sinus
underwent surgical resection [12]. Renal cell carcinoma
Table 4 Clinical syndromes associated with skull-base metastases
Clinical syndrome This study Greenberg
et al. [2]
Orbital syndrome 4 (20%) 3 (7%)
Parasellar syndrome 7 (35%) 7 (16%)
Middle fossa (Gasserian ganglion) syndrome 4 (20%) 15 (35%)
Jugular foramen syndrome 3 (15%) 9 (21%)
Occipital condyle syndrome 2 (10%) 9 (21%)
Total 20 43
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123and sarcoma were the most common primary malignancies.
Overall median actual survival was 16.5 months.
Recent advances in chemotherapy have contributed in
treatment of metastatic skull tumors and systemic bone
metastasis. Bisphosphonates (BPs) are effective as a palli-
ative treatment for painful bone metastasis and other bone
complications [13]. Zoledronate, a BP, has been increas-
ingly used for patients because of improved convenience in
clinical application. However, long-term treatment with
BPs may cause mandibular necrosis; patients are advised to
consult an oral surgeon before undergoing treatment with
BPs [14]. Other new bone-speciﬁc medications which may
contribute to improving clinical manifestations and survival
areanisotope,
89Sr,andanantibody forreceptoractivatorof
NF-kappa B (RANKL), denosumab [15].
Conclusion
SkullmetastasescanbediagnosedbyuseofroutineheadMR
images acquired for screening or assessing brain metastases.
Here we have proposed a simple system of classiﬁcation for
succinct and clear description of those lesions. Early diag-
nosis then treatment with irradiation can give patients a
better quality of life.
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